Promising drug cocktail aims to shrink penile cancer before surgery
NCT ID NCT07518979
First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 5 times
Summary
This phase II trial tests a combination of two drugs—Becotatug vedotin (a targeted therapy that attacks cancer cells with a specific protein) and Pucotenlimab (an immunotherapy that boosts the immune system)—in men with advanced penile cancer that is hard to treat with surgery alone. About 60 participants will receive the drugs before surgery to see if it shrinks the tumor enough for complete removal. The goal is to improve outcomes and possibly reduce the extent of surgery needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Becotatug vedotin (targeted therapy) and Pucotenlimab (immunotherapy)
- What this could lead to
- If successful, this combination could shrink advanced penile cancer enough to allow complete surgical removal, potentially improving survival and reducing the need for more extensive surgery.
- What could go wrong
- This is an early phase II trial with only 60 participants, so results may not apply to everyone. Side effects like skin rash, immune reactions, and organ stress are possible, and the treatment may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PENILE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- Penis transplants could restore form and function for wounded warriors
- New drug combo targets HPV-Driven cancers in phase II trial
- Double antibody attack: early trial combines immune and Growth-Signal blockers against advanced cancers
- Triple immunotherapy attack shows promise against Hard-to-Treat HPV cancers
- New hope for rare penile cancer: targeted drug combo shows promise